blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1664798

EP1664798 - NON-PEPTIDE AGONISTS AND ANTAGONISTS OF ADRENOMEDULLIN AND GASTRIN RELEASING PEPTIDE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  28.03.2014
Database last updated on 07.10.2024
Most recent event   Tooltip23.03.2018Lapse of the patent in a contracting statepublished on 25.04.2018  [2018/17]
Applicant(s)For all designated states
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
Suite 325, 6011 Executive Boulevard
Bethesda, MD 20852 / US
[2013/21]
Former [2006/23]For all designated states
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services
Suite 325, 6011 Executive Boulevard
Bethesda, MD 20852 / US
Inventor(s)01 / CUTTITTA, Frank
7908 Hope Valley Court
Adamstown, MD 21710 / US
02 / MARTINEZ, Alfredo
5225 Pooks Hill Road
Apt. 1614S
Bethesda, MD 20814 / US
 [2013/21]
Former [2006/23]01 / CUTTITTA, Frank
7908 Hope Valley Court
Adamstown, MD 21710 / US
02 / MARTINEZ, Alfredo
5225 Pooks Hill Road, Apt. 1614S
Bethesda, MD 20814 / US
Representative(s)Lord, Hilton David
Marks & Clerk LLP
90 Long Acre
London WC2E 9RA / GB
[N/P]
Former [2013/21]Lord, Hilton David
Marks & Clerk LLP
90 Long Acre
London
WC2E 9RA / GB
Former [2006/23]Lord, Hilton David
Marks & Clerk 90 Long Acre
London WC2E 9RA / GB
Application number, filing date04783513.708.09.2004
[2006/23]
WO2004US29293
Priority number, dateUS20030500650P08.09.2003         Original published format: US 500650 P
US20040569625P11.05.2004         Original published format: US 569625 P
[2006/23]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2005026741
Date:24.03.2005
Language:EN
[2005/12]
Type: A2 Application without search report 
No.:EP1664798
Date:07.06.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 24.03.2005 takes the place of the publication of the European patent application.
[2006/23]
Type: B1 Patent specification 
No.:EP1664798
Date:22.05.2013
Language:EN
[2013/21]
Search report(s)International search report - published on:EP18.08.2005
ClassificationIPC:G01N33/74, A61K31/194, A61K31/4196, A61K31/445, A61K31/4453, A61K31/45, // A61P1/00, A61P17/00, A61P27/02, A61P9/08, A61P9/10, A61P3/10, A61P35/00, A61P9/02
[2012/36]
CPC:
A61K31/52 (EP,US); A61K31/192 (EP,US); A61K31/194 (EP,US);
A61K31/197 (EP,US); A61K31/4196 (EP,US); A61K31/433 (EP,US);
A61K31/439 (EP,US); A61K31/44 (EP,US); A61K31/445 (EP,US);
A61K31/4453 (EP,US); A61K31/45 (EP,US); A61K38/22 (EP,US);
A61P1/00 (EP); A61P11/00 (EP); A61P17/00 (EP);
A61P27/02 (EP); A61P3/10 (EP); A61P35/00 (EP);
A61P9/02 (EP); A61P9/08 (EP); A61P9/10 (EP);
G01N33/68 (US); G01N33/74 (EP,US); G01N2333/5758 (EP,US);
G01N2500/04 (EP,US) (-)
C-Set:
A61K38/22, A61K2300/00 (EP,US)
Former IPC [2006/23]G01N33/74, A61K31/194, A61K31/4196, A61K31/445, A61K31/4453, A61K31/45, A61P9/08, A61P9/10, A61P3/10, A61P35/00, A61P9/02
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/23]
TitleGerman:NICHT PEPTIDISCHE AGONISTEN UND ANTAGONISTEN VON ADRENOMEDULLIN UND GASTRIN FREISETZENDE PEPTIDE[2006/23]
English:NON-PEPTIDE AGONISTS AND ANTAGONISTS OF ADRENOMEDULLIN AND GASTRIN RELEASING PEPTIDE[2006/23]
French:AGONISTES ET ANTAGONISTES NON PEPTIDIQUES D'ADRENOMEDULLINE ET PEPTIDE DE LIBERATION GASTRIQUE[2006/23]
Entry into regional phase29.03.2006National basic fee paid 
29.03.2006Designation fee(s) paid 
29.03.2006Examination fee paid 
Examination procedure30.03.2006Amendment by applicant (claims and/or description)
30.03.2006Examination requested  [2006/23]
27.01.2009Despatch of a communication from the examining division (Time limit: M06)
06.08.2009Reply to a communication from the examining division
31.03.2011Despatch of a communication from the examining division (Time limit: M04)
01.08.2011Reply to a communication from the examining division
27.07.2012Cancellation of oral proceeding that was planned for 17.09.2012
17.09.2012Date of oral proceedings (cancelled)
07.11.2012Communication of intention to grant the patent
13.11.2012Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
12.12.2012Communication of intention to grant the patent
09.04.2013Fee for grant paid
09.04.2013Fee for publishing/printing paid
Divisional application(s)EP11000695.4  / EP2339351
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  27.01.2009
Opposition(s)25.02.2014No opposition filed within time limit [2014/18]
Fees paidRenewal fee
27.09.2006Renewal fee patent year 03
26.09.2007Renewal fee patent year 04
25.09.2008Renewal fee patent year 05
25.09.2009Renewal fee patent year 06
27.09.2010Renewal fee patent year 07
26.09.2011Renewal fee patent year 08
25.09.2012Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU08.09.2004
AT22.05.2013
BE22.05.2013
CY22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
IT22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
TR22.05.2013
BG22.08.2013
GR23.08.2013
ES02.09.2013
GB08.09.2013
IE08.09.2013
LU08.09.2013
PT23.09.2013
CH30.09.2013
LI30.09.2013
[2016/41]
Former [2015/34]HU08.09.2004
AT22.05.2013
BE22.05.2013
CY22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
IT22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
TR22.05.2013
BG22.08.2013
GR23.08.2013
ES02.09.2013
GB08.09.2013
IE08.09.2013
LU08.09.2013
PT23.09.2013
CH30.09.2013
LI30.09.2013
Former [2015/32]AT22.05.2013
BE22.05.2013
CY22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
IT22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
TR22.05.2013
BG22.08.2013
GR23.08.2013
ES02.09.2013
GB08.09.2013
IE08.09.2013
PT23.09.2013
CH30.09.2013
LI30.09.2013
Former [2015/30]AT22.05.2013
BE22.05.2013
CY22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
IT22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
ES02.09.2013
GB08.09.2013
IE08.09.2013
PT23.09.2013
CH30.09.2013
LI30.09.2013
Former [2014/34]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
IT22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
ES02.09.2013
GB08.09.2013
IE08.09.2013
PT23.09.2013
CH30.09.2013
LI30.09.2013
Former [2014/33]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
IT22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
ES02.09.2013
IE08.09.2013
PT23.09.2013
Former [2014/20]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
IT22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
ES02.09.2013
PT23.09.2013
Former [2014/14]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
IT22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
ES02.09.2013
PT23.09.2013
Former [2014/11]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
IT22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
ES02.09.2013
PT23.09.2013
Former [2014/10]AT22.05.2013
BE22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
ES02.09.2013
PT23.09.2013
Former [2014/09]AT22.05.2013
BE22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
BG22.08.2013
GR23.08.2013
ES02.09.2013
PT23.09.2013
Former [2014/06]AT22.05.2013
BE22.05.2013
FI22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
BG22.08.2013
GR23.08.2013
ES02.09.2013
PT23.09.2013
Former [2013/50]AT22.05.2013
FI22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
BG22.08.2013
GR23.08.2013
ES02.09.2013
PT23.09.2013
Former [2013/49]AT22.05.2013
FI22.05.2013
SE22.05.2013
SI22.05.2013
GR23.08.2013
ES02.09.2013
PT23.09.2013
Former [2013/48]AT22.05.2013
ES02.09.2013
PT23.09.2013
Former [2013/47]PT23.09.2013
Cited inInternational search[X]FR2241313  (SANDOZ SA [CH]) [X] 9,10,53,54 * claims 1,13,14 *;
 [A]WO9707214  (US GOV HEALTH & HUMAN SERV [US], et al) [A] 1-4,9-28,47,48,51-54,57,58,61 * abstract *;
 [X]WO9905299  (UNIV BOSTON [US]) [X] 9,10,35-37,55,56,61 * claims 16,27,40 *;
 [X]WO0030630  (LINDEN BIOTECHNOLOGY INC [US], et al) [X] 9,10,35-37,55,56,61 * figure 1; claim 9 *;
 [A]EP0806418  (NIPPON SHOJI KAISHA LIMITED [JP]) [A] 49,59,66-75 * abstract *
 [X]  - LOOKER, J. H. ET AL, "1,2,3-Thiadiazoles as potential antineoplastic agents. I. Synthesis of novel 4-monosubstituted and 4,5-disubstituted derivatives Physiologically active compounds. III. Hydrochlorides of amino esters of phenylcyclohexylglycolic acids, of amides of benzilic, phenylcyclohexyl- and dicyclohexylglycolic,", JOURNAL OF HETEROCYCLIC CHEMISTRY , 2(4), 348-54 CODEN: JHTCAD; ISSN: 0022-152X, (1965), XP002314287 [X] 9,10,17-19,53,54 * page 352, column L, line 6 - line 12; table I *

DOI:   http://dx.doi.org/10.1002/jhet.5570020405
 [X]  - TMEJ C ET AL, "A COMBINED HANSCH/FREE-WILSON APPROACH AS PREDICTIVE TOOL IN QSAR STUDIES ON PROPAFENONE-TYPE MODULATORS OF MULTIDRUG RESISTANCE", ARCHIV DER PHARMAZIE, VCH VERLAGSGESELLSCHAFT MBH, WEINHEIM, DE, (1998), vol. 331, no. 7/8, ISSN 0365-6233, pages 233 - 240, XP000881287 [X] 9,10,17-19,53,54 * abstract; page 233, left-hand column, first paragraph; tables 1-2; figure 1 *

DOI:   http://dx.doi.org/10.1002/(SICI)1521-4184(199807)331:7/8<233::AID-ARDP233>3.3.CO;2-U
 [X]  - MURAD S ET AL, "STRUCTURE-ACTIVITY RELATIONSHIP OF MINOXIDIL ANALOGS AS INHIBITORS OF LYSYL HYDROXYLASE IN CULTURED FIBROBLASTS1", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, NEW YORK, US, US, (1992), vol. 292, no. 1, ISSN 0003-9861, pages 234 - 238, XP000564071 [X] 9,10,53,54 * abstract; table I; page 237, paragraph joining left- and right-hand columns; paragraph joining pages 237 and 238 *

DOI:   http://dx.doi.org/10.1016/0003-9861(92)90073-6
 [X]  - EAKIN A E ET AL, "COMPARATIVE COMPLEMENT SELECTION IN BACTERIA ENABLES SCREENING FOR LEAD COMPOUNDS TARGETED TO A PURINE SALVAGE ENZYME OF PARASITES", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, (199503), vol. 39, no. 3, ISSN 0066-4804, pages 620 - 625, XP001055590 [X] 9,10,53,54 * abstract *
 [PX]  - MARTÍNEZ A ET AL, "Identification of vasoactive nonpeptidic positive and negative modulators of adrenomedullin using a neutralizing antibody-based screening strategy", ENDOCRINOLOGY 2004 UNITED STATES, (200408), vol. 145, no. 8, ISSN 0013-7227, pages 3858 - 3865, XP009042699 [PX] 1-75 * abstract *

DOI:   http://dx.doi.org/10.1210/en.2003-1251
 [PX]  - GASPARETTO M ET AL, "Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, (200409), vol. 292, no. 1-2, ISSN 0022-1759, pages 59 - 71, XP004550500 [PX] 9,10,20-28,53,54 * abstract *

DOI:   http://dx.doi.org/10.1016/j.jim.2004.06.003
 [A]  - EGUCHI SATORU ET AL, "Structure-activity relationship of adrenomedullin, a novel vasodilatory peptide, in cultured rat vascular smooth muscle cells", ENDOCRINOLOGY, BALTIMORE, MD, US, (1994), vol. 135, no. 6, ISSN 0013-7227, pages 2454 - 2458, XP002193142 [A] 1-4,9-28,47,48,51-54,57,58,61 * abstract *

DOI:   http://dx.doi.org/10.1210/en.135.6.2454
 [A]  - AMIR S M ET AL, "POLYPHLORETIN PHOSPHATE AN ANTAGONIST OF THYROTROPIN ACTION EVIDENCE FOR AN INTERACTION WITH THE HORMONE RATHER THAN THE RECEPTOR", ENDOCRINOLOGY, (1985), vol. 117, no. 3, ISSN 0013-7227, pages 860 - 868, XP009042800 [A] * abstract *
 [A]  - HEUSER MARKUS ET AL, "The inhibition of angiogenesis and microcirculation in renal cell carcinoma spheroids by gastrin releasing peptide receptor (GRP-R) antagonism depends on the time of treatment initiation.", JOURNAL OF UROLOGY, & 98TH ANNUAL MEETING OF THE AMERICAN UROLOGICAL ASSOCIATION (AUA); CHICAGO, IL, USA; APRIL 26-MAY 02, 2003, (200304), vol. 169, no. 4 Supplement, ISSN 0022-5347, page 207, XP009042804 [A] * abstract *

DOI:   http://dx.doi.org/10.1097/01.ju.0000051222.09122.54
 [X]  - CHERNOV, V. A. ET AL, "Antiblastomic activity of sydnone imines", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (1964), Database accession no. 1964:406942, URL: STN, XP002331366 [X] 9,10,35-37,55,56,61 * abstract *
 [X]  - DAENIKER, H. U. ET AL, "Chemotherapeutic studies in the heterocyclic series. XVIII. Polymethylenedi(sydnones) and polymethylenedi(hydrazines)", HELVETICA CHIMICA ACTA , 40, 918-32 CODEN: HCACAV; ISSN: 0018-019X, (1957), XP009048688 [X] 9,10,35-37,55,56,61 * compound IVa on page 920; last paragraph (foot notes) on page 925 *

DOI:   http://dx.doi.org/10.1002/hlca.19570400406
 [X]  - THOMAS F ET AL, "ANTITUMORAL ACTIVITY OF BOMBESIN ANALOGUE ON SMALL CELL LUNG CANCER XENOGRAFTS RELATIONSHIP WITH BOMBESIN RECEPTOR EXPRESSION", CANCER RESEARCH, (1992), vol. 52, no. 18, ISSN 0008-5472, pages 4872 - 4877, XP001206441 [X] 65 * abstract *
 [PX]  - BAJO A M ET AL, "BOMBESIN ANTAGONISTS INHIBIT PROANGIOGENIC FACTORS IN HUMAN EXPERIMENTAL BREAST CANCERS", BRITISH JOURNAL OF CANCER, LONDON, GB, (20040112), vol. 90, no. 1, ISSN 0007-0920, pages 245 - 252, XP001183666 [PX] 62-65 * abstract *

DOI:   http://dx.doi.org/10.1038/sj.bjc.6601404
 [A]  - CUTTITTA F ET AL, "BOMBESIN-LIKE PEPTIDES CAN FUNCTION AS AUTOCRINE GROWTH FACTORS IN HUMAN SMALL-CELL LUNG CANCER", NATURE (LONDON), (1985), vol. 316, no. 6031, ISSN 0028-0836, pages 823 - 826, XP001206814 [A] 5-8,29-46,49-52,55,56,59-61 * page 823, right-hand column, second paragraph; page 824, left-hand column, second paragraph; figure 3; page 826, left-hand column, lines 1-4 *

DOI:   http://dx.doi.org/10.1038/316823a0
 [A]  - ASHWOOD V ET AL, "PD 176252 - The First High Affinity Non-peptide Gastrin-Releasing Peptide (BB2) Receptor Antagonist", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, (19980922), vol. 8, no. 18, ISSN 0960-894X, pages 2589 - 2594, XP004138276 [A] 5-8,29-46,49-52,55,56,59-61 * abstract *

DOI:   http://dx.doi.org/10.1016/S0960-894X(98)00462-4
by applicantFR2241313
    - LOOKER JH ET AL., JOURNAL OF HETEROCYCLIC CHEMISTRY, (1965), vol. 2, no. 4, pages 348 - 354
    - TMEJ C ET AL., ARCHIV DER PHARMAZIE, (1998), vol. 331, no. 7/8, pages 233 - 240
    - MURAD S ET AL., ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, (1992), vol. 292, no. 1, pages 234 - 238
    - EAKIN AE ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (1995), vol. 39, no. 3, pages 620 - 625
    - MARTINEZ A ET AL., ENDOCRINOLOGY, (2004), vol. 145, no. 8, pages 3858 - 3865
    - NAKAJIMA; ANSELME, J. ORG. CHEM., (1983), vol. 48, pages 1444 - 1448
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.